Aegis Capital Initiates Neostem at Buy on Stem Cell Platforms

In a report published Monday, Aegis Capital analyst Raghuram Selvaraju initiated coverage on Neostem with a Buy rating and $2.50 price target.

http://www.benzinga.com/analyst-ratings/analyst-color/13/06/3699477/update-aegis-capital-initiates-neostem-at-buy-on-stem-ce